Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.
Feature|Articles|July 6, 2026
FDA decisions in eye care: A first-half 2026 recap
Author(s)Abigail Lewis, Content Intern
Fact checked by: Jordana Joy, Editor
A summary of major FDA approvals and CRLs in eye care from the first half of 2026.
Advertisement
Advertisement
The first half of 2026 has delivered a notable mix of FDA approvals, complete response letters, and regulatory milestones across several therapeutic areas relevant to optometric practice. From first-in-class presbyopia drops and EDOF contact lenses to new tools for thyroid eye disease and ongoing setbacks in dry eye, the regulatory landscape has moved quickly. Below is a summary of the major decisions optometrists should be aware of heading into the second half of the year.
Related to this article
Are our children truly ready to see—and learn?
Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his AAOpt 2026 presentation "Photobiomodulation in Age-Related Macular Degeneration: Evidence, Mechanisms, and Clinical Integration."
Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.
Eric Schmidt, OD, FAAO, presented his poster "Patient-Reported Blurred Vision Improvement with Cyclosporine 0.1%/PFBP in Dry Eye Disease with Severe Central Corneal Staining: Phase 3 Pool" at AAOpt 2026.
Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.
A young woman had years of headaches, dizziness, and intolerance of her phone despite normal routine eye examinations. A modest prism gave her immediate relief.
Raman Bhakhri, OD, FAAO, details a session given with Denise Skiadopoulos, OD, FAAO, during the annual AAOpt meeting in Anaheim, California.
Advertisement
Advertisement